Conversely, in the ongoing WT1 peptide-based immunotherapy phase I/II trials, frequent clinical responses and even drastic tumor regression have been reported for leukemia [153], myelodysplastic syndrome [154] and solid tumors, such as lung [153,155] and breast cancers [153,156]. The gene discussed is WT1; the disease is breast carcinoma.